NASDAQ Stocks
· May 10, 2025 11:20 AM EDT
Not market news
Madrigal Pharmaceuticals Reports Positive Two-Year Results for Rezdiffra in Phase 3 MAESTRO-NAFLD-1 Trial for MASH Cirrhosis
Madrigal Pharmaceuticals reported significant two-year trial results for Rezdiffra, showing improved liver stiffness and reduced portal hypertension risk.
AI brief
Pulse reads the full article- What happened
- Why it matters
- What to watch
Sign in to get the AI brief. Pulse explains what happened, why it matters, what to watch and who's exposed. Free for members.
Sign in to read the brief
